JYOTHI B. NAIR^1,2, ANU MARY JOSEPH³, SANOOP P.⁴, MANU M. JOSEPH^5,*

BIOCELL, Vol.48, No.11, pp. 1579-1602, 2024, DOI:10.32604/biocell.2024.054879 - 07 November 2024

Abstract Nanoparticles represent a heterogeneous collection of materials, whether natural or synthetic, with dimensions aligning in the nanoscale. Because of their intense manifestation with the immune system, they can be harvested for numerous bio-medical and biotechnological advancements mainly in cancer treatment. This review article aims to scrutinize various types of nanoparticles that interact differently with immune cells like macrophages, dendritic cells, T lymphocytes, and natural killer (NK) cells. It also underscores the importance of knowing how nanoparticles influence immune cell functions, such as the production of cytokines and the presentation of antigens which are crucial for… More >

SULING XU¹, XIAO LI², WENXUE MA^3,*

Oncology Research, Vol.32, No.11, pp. 1701-1708, 2024, DOI:10.32604/or.2024.055161 - 16 October 2024

Abstract The environment surrounding a tumor, known as the tumor microenvironment (TME), plays a role in how cancer progresses and responds to treatment. It poses both challenges and opportunities for improving cancer therapy. Recent progress in understanding the TME complexity and diversity has led to approaches for treating cancer. This perspective discusses the strategies for targeting the TME, such as adjusting networks using extracellular vesicles to deliver drugs and enhancing immune checkpoint inhibitors (ICIS) through combined treatments. Furthermore, it highlights adoptive cell transfer (ACT) therapies as an option for tumors. By studying how components of the More >

SHUBHRA CHANDRA^1,2, JENNIFER C. WILSON^1,2, DAVID GOOD³, MING Q. WEI^1,2,*

Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987 - 18 September 2024

Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More > Graphic Abstract

QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383 - 15 November 2023

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*

Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924 - 25 June 2023

Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen More > Graphic Abstract

Xue Cui^1,2, Min Peng², Honglei Chen^1,*

Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641 - 31 December 2022

Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and More >